T-cell TGF-β signaling abrogation restricts medulloblastoma progression

David Gate, Moise Danielpour, Javier Rodriguez, Gi Bum Kim, Rachelle Levy, Serguei Bannykh, Joshua J. Breunig, Susan M. Kaech, Richard A. Flavell*, Terrence Town

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Cancer cell secretion of TGF-β is a potent mechanism for immune evasion. However, little is known about how central nervous system tumors guard against immune eradication. We sought to determine the impact of T-cell TGF-β signaling blockade on progression of medulloblastoma (MB), the most common pediatric brain tumor. Genetic abrogation of T-cell TGF-β signaling mitigated tumor progression in the smoothened A1 (SmoA1) transgenic MB mouse. T regulatory cells were nearly abolished and antitumor immunity was mediated by CD8 cytotoxic T lymphocytes. To define the CD8 T-cell subpopulation responsible, primed CD8 T cells were adoptively transferred into tumor-bearing immunocompromised SmoA1 recipients. This led to generation of CD8 +/killer cell lectin-like receptor G1 high (KLRG1hi)/IL- 7Rlo short-lived effector cells that expressed granzyme B at the tumor. These results identify a cellular immune mechanism whereby TGF-β signaling blockade licenses the T-cell repertoire to kill pediatric brain tumor cells.

Original languageEnglish (US)
Pages (from-to)E3458-E3466
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number33
DOIs
StatePublished - Aug 19 2014

Keywords

  • Cancer immunology
  • Neuro-oncology
  • Neuroimmunology

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'T-cell TGF-β signaling abrogation restricts medulloblastoma progression'. Together they form a unique fingerprint.

Cite this